TELA Bio (TELA) Net Cash Flow Growth (3y) (2021 - 2026)
TELA Bio (TELA) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 269.22% |
| 10 | TELA Bio | 36.75 Mn | 6.32 Mn | 13.94 Mn | -31.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.26% |
| Mar 31, 2026 | 1.84% |
| Dec 31, 2025 | 55.06% |
| Sep 30, 2025 | -30.10% |
| Jun 30, 2025 | -13.72% |
| Mar 31, 2025 | 3.84% |
| Dec 31, 2024 | 77.86% |
| Sep 30, 2024 | -10.58% |
| Jun 30, 2024 | -24.30% |
| Mar 31, 2024 | -3.97% |
| Dec 31, 2023 | -16.51% |
| Sep 30, 2023 | -20.66% |
| Jun 30, 2023 | -7.40% |
| Mar 31, 2023 | -45.28% |
| Dec 31, 2022 | -33.02% |
| Sep 30, 2022 | 92.65% |
| Jun 30, 2022 | -41.18% |
| Mar 31, 2022 | -11.65% |
| Dec 31, 2021 | -38.06% |